News

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...
The Food and Drug Administration has approved the world’s only twice-a-year shot to prevent HIV. In two groundbreaking ...
The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...
The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...
HIV and global health activists say the deployment of Gilead’s twice-a-year HIV prevention shot is the world’s best chance to ...
FRIDAY, June 20, 2025 (HealthDay News) — A new shot to prevent HIV infection has just been approved — and it only needs to be ...
Emmanuel Cherem, a 25-year-old gay man in Nigeria, tested positive for HIV two months after U.S. President Donald Trump's ...
Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...
The drug, lamivudine, appears to improve vision that’s being threatened by diabetic macular edema (DME), an eye condition in ...
The approach employed by the research team could be used against other diseases—including COVID-19 and influenza.
The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.
Colombian billionaire Jaime Gilinski Bacal is open to selling his majority stake in British lender Metro Bank and has ...